80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]沈明虹.上皮性卵巢癌HMGB3表達及預后價值的生物信息學分析[J].福建醫(yī)藥雜志,2023,45(06):1-3.
　SHEN Minghong.Analysis of HMGB3 expression and prognostic value in epithelial ovarian cancer based on bioinformatics[J].FUJIAN MEDICAL JOURNAL,2023,45(06):1-3.
點擊復制

上皮性卵巢癌HMGB3表達及預后價值的生物信息學分析()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期數(shù):
2023年06期
頁碼:
1-3
欄目:
臨床研究
出版日期:
2023-12-15

文章信息/Info

Title:
Analysis of HMGB3 expression and prognostic value in epithelial ovarian cancer based on bioinformatics
文章編號:
1002-2600(2023)06-0001-03
作者:
沈明虹
福建省立醫(yī)院婦科(福州 350001)
Author(s):
SHEN Minghong
Department of Gynecology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China
關鍵詞:
上皮性卵巢癌;  高遷移率族蛋白B3;  生物信息學;  預后
Keywords:
epithelial ovarian cancer;  high mobility group box B3;  bioinformatics;  prognosis
分類號:
R737.31
文獻標志碼:
A
摘要:
目的 探討高遷移率族蛋白B3(HMGB3)在上皮性卵巢癌(EOC)中的表達及其與EOC患者預后的關系。方法 應用GEPIA2、UALCAN及TIMER 2.0數(shù)據(jù)庫分析HMGB3在EOC組織中的表達水平及其與預后的相關性; 通過UALCAN分析HMGB3可能參與調控的信號通路; 利用TIMER 2.0分析HMGB3表達對腫瘤微環(huán)境中免疫細胞浸潤的影響,分析HMGB3基因與PARP1、PARP2基因表達的相關性。結果 1)EOC組織中HMGB3的表達水平顯著上調(P<0.05); 2)HMGB3高表達EOC患者的無病生存率、總生存率均顯著優(yōu)于HMGB3低表達患者(P均<0.05); 3)HMGB3高表達與CD4+T細胞、CD8+T細胞的高豐度相關(r=0.191,0.153,P均<0.05); 4)HMGB3基因與PARP1、PARP2基因表達呈正相關(r=0.308,0.398,P均<0.001)。結論 HMGB3在EOC組織中顯著上調,其高表達預示EOC患者預后良好,并與PARP1、PARP2基因表達相關,可作為EOC預后相關的潛在生物標志物。
Abstract:
Objective To explore the expression of high mobility group box B3(HMGB3)in epithelial ovarian cancer(EOC)and its relationship with the prognosis of EOC patients. Methods GEPIA2, UALCAN and TIMER 2.0 databases were used to analyze the expression level of HMGB3 in EOC tissues, its correlation with EOC patients prognosis, the signaling pathways that HMGB3 may participate in regulation, the effects of HMGB3 expression on immune cell infiltration in tumor microenvironment, and the correlations between HMGB3 and PARP1/2.Results The expression levels of HMGB3 in EOC tissues were significantly upregulated(P<0.05).Disease-free survival and overall survival of EOC patients with high expression levels of HMGB3 were significantly higher than those with low expression levels of HMGB3(P<0.05).High expression levels of HMGB3 were correlated with the high abundance of CD4+T cells and CD8+T cells [correlation coefficients(r)were 0.191 and 0.153, respectively, both P<0.05].HMGB3 was positively correlated with the PARP1 and PARP2 genes(r=0.308, P<0.001; r=0.398, P<0.001).Conclusion HMGB3 is significantly upregulated in EOC tissues.High expression levels of HMGB3 predicts a good prognosis in EOC patients and is associated with the expression levels of PARP1 and PARP2 genes, which can serve as a potential biomarker for EOC patients.

參考文獻/References:

[1] Odunsi K.Immunotherapy in ovarian cancer[J].Ann Oncol,2017, 28(suppl_8):viii1-viii7.
[2] Fang J,Ge X,Xu W, et al.Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer[J].J Cell Physiol,2020, 235(4):3438-3446.
[3] Wen B,Wei Y T,Zhao K.The role of high mobility group protein B3(HMGB3)in tumor proliferation and drug resistance[J].Mol Cell Biochem, 2021, 476(4):1729-1739.
[4] Xie X,Pan J,Han X, et al.Downregulation of microRNA-532-5p promotes the proliferation and invasion of bladder cancer cells through promotion of HMGB3/Wnt/β-catenin signaling[J].Chem Biol Interact, 2019, 300:73-81.
[5] Song N, Wang B,Feng G,et al.Knockdown of high mobility group box 3 impairs cell viability and colony formation but increases apoptosis in A549 human non-small cell lung cancer cells[J].Oncol Lett,2019, 17(3):2937-2945.
[6] Mukherjee A,Huynh V,Gaines K,et al.Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin[J].Cancer Res, 2019,79(13):3185-3191.
[7] Zhou X,Zhang Q,Liang G,et al.Overexpression of HMGB3 and its prognostic value in breast cancer[J].Front Oncol,2022, 12:1048921.
[8] Gong W,Guo Y,Yuan H,et al.HMGB3 is a potential therapeutic target by affecting the migration and proliferation of colorectal cancer[J].Front Cell Dev Biol, 2022, 10:891482.
[9] Zheng X,Wang X,He Y, et al.Systematic analysis of expression profiles of HMGB family members for prognostic application in non-small cell lung cancer[J].Front Mol Biosci, 2022,9:844618.
[10] Li M,Cai Y,Zhao H,et al.Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients[J].Tumour Biol, 2015, 36(6):4785-4792.
[11] Shimizu S,Hiratsuka H,Koike K, et al.Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma[J].Cancer Med, 2019,8(1):80-93.
[12] Oda K,Kato K,Nakamura M, et al.Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infifiltrating lymphocytes in lung cancer patients treated with pembrolizumab[J].Lung Cancer, 2018,118:171-172.
[13] Batista F D,Harwood N E.The who, how and where of antigen presentation to b cells[J].Nat Rev Immunol, 2009, 9(1):15-27.
[14] Revythis A,Limbu A,Mikropoulos C, et al.Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer[J].Int J Environ Res Public Health, 2022, 19(14):8577.
[15] Zuo W W,Zhao C F,Li Y, et al.High expression of PARP1 in tumor and stroma cells predicts different prognosis and platinum resistance in patients with advanced epithelial ovarian cancer[J].Front Oncol, 2022,12: 931445.
[16] Revythis A,Limbu A,Mikropoulos C, et al.Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer[J].Int J Environ Res Public Health, 2022, 19(14):8577.
[17] Ma H,Qi G,Han F, et al.HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer[J].Cell Death Dis, 2022, 13(3):263.

相似文獻/References:

[1]劉小梅,莊良武,章斌斌.術前中性粒細胞/淋巴細胞比值對上皮性卵巢癌患者術后生存率的影響[J].福建醫(yī)藥雜志,2021,43(04):7.
　LIU Xiaomei,ZHUANG Liangwu,ZHANG Binbin.Preoperative neutrophil/lymphocyte ratio predicts postoperative survival rate in patients with epithelial ovarian cancer[J].FUJIAN MEDICAL JOURNAL,2021,43(06):7.

備注/Memo

備注/Memo:
基金項目:福建省衛(wèi)健委中青年骨干人才培養(yǎng)項目(2021GGA008)
更新日期/Last Update: 2023-12-15